Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China

Homologous recombination deficiency (HRD) is an approved predictive biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer. However, the proportion of positive HRD in the real world and the relationship between HRD status and PARPi in Chinese ovarian cancer patients remain u...

Full description

Bibliographic Details
Main Authors: Jing Ni, Wenwen Guo, Qian Zhao, Xianzhong Cheng, Xia Xu, Rui Zhou, Hongyuan Gu, Chen Chen, Xiaoxiang Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
HRD
PARPi
predictive biomarker
ovarian cancer
Chinese population
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.746571/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.746571/full

Similar Items